Immunology

Addressing disparities in biologic drug development in the United States



http://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/067e0643-f5ff-437d-96a8-7c40440c9298/gr1.jpg

Key words

Racial and ethnic minorities are underrepresented in clinical trials of mAbs (“biologics”) for allergic diseases, but this is not due to a paucity of minorities with allergic diseases.

Underrepresentation of blacks, smokers, and obese patients in studies of monoclonal antibodies for asthma.